clinical trial · NCT03383458
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Bristol-Myers Squibb·phase3·active not recruiting·n = 545
Hepatocellular CarcinomaLiver CancerNivolumabPlacebo
brief summary
This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation, and who are at high risk of recurrence
started
Apr 18, 2018
primary completion
May 27, 2026
completion
May 27, 2031
last updated
Jul 31, 2026
official title
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol